Related Experiment Video
Updated: Aug 19, 2026
MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent
Published on: September 3, 2013
Therapeutic efficacy of recombinant tumor necrosis factor alpha in an experimental model of human prostatic carcinoma
E R Sherwood1, T R Pitt Ford, C Lee
1Department of Urology, Northwestern University Medical School, Chicago, Illinois 60611.
Abstract:
Prostatic carcinoma represents the second leading cause of cancer mortality in men and is responsible for over 25,000 deaths each year. Currently, no curative therapy is available for metastatic carcinoma of the prostate. The present studies were undertaken to assess the efficacy of recombinant tumor necrosis factor alpha (TNF) in the therapy of experimental prostatic carcinoma. TNF was cytotoxic to the prostate cancer cell lines PC3, DU145, and LNCAP but not benign prostatic epithelial and stromal cells in vitro. The sensitivity of the prostatic carcinoma lines to TNF-mediated cytotoxicity was enhanced by the presence of actinomycin D. Intravenous administration of TNF (50-100 micrograms/kg) to nude mice bearing subcutaneous PC3 tumors resulted in significant inhibition of primary tumor growth compared to control. TNF was also effective in reducing the growth of intraabdominal PC3 tumors induced by intrasplenic injection of PC3. Furthermore, the incidence of microscopic PC3 foci in the spleen, liver, lung, and diaphragm was diminished in mice receiving TNF therapy. These studies demonstrate the potential of TNF in the therapy of human prostatic carcinoma.
Insights
Recombinant tumor necrosis factor alpha (TNF) shows promise in treating prostate cancer. Studies indicate TNF effectively inhibits tumor growth and reduces metastasis in experimental models, offering a potential new therapy for advanced prostate carcinoma.
Area of Science:
- Oncology
- Immunology
- Pharmacology
Background:
- Prostatic carcinoma is a leading cause of cancer mortality in men, with limited curative options for metastatic disease.
- Current treatments for advanced prostate cancer are insufficient, highlighting the need for novel therapeutic strategies.
Purpose of the Study:
- To evaluate the efficacy of recombinant tumor necrosis factor alpha (TNF) in treating experimental prostate cancer.
- To assess TNF's cytotoxic effects on prostate cancer cell lines and its therapeutic potential in vivo.
Main Methods:
- In vitro cytotoxicity assays using prostate cancer cell lines (PC3, DU145, LNCAP) and benign prostatic cells.
- In vivo studies involving nude mice with subcutaneous and intra-abdominal PC3 tumors.
- Administration of TNF intravenously and assessment of tumor growth inhibition and metastasis reduction.
Main Results:
- TNF demonstrated selective cytotoxicity against prostate cancer cell lines but not normal prostatic cells in vitro.
- The combination of TNF and actinomycin D enhanced the sensitivity of cancer cells to TNF.
- Intravenous TNF administration significantly inhibited primary tumor growth and reduced the incidence of metastasis in mice.
Conclusions:
- Recombinant tumor necrosis factor alpha (TNF) exhibits significant anti-cancer activity against experimental prostate carcinoma.
- TNF shows potential as a therapeutic agent for human prostatic carcinoma, particularly in advanced or metastatic stages.
- Further research into TNF-based therapies could lead to improved treatment outcomes for prostate cancer patients.
